Dallas, TX (PressExposure) April 20, 2010 -- ReportsandReports announce it will carry The Lifestyle Disorders Market Outlook to 2014: Reimbursement issues, market dynamics, pipeline compounds Market Research Report in its Store.
Lifestyle drugs have been a much debated segment of therapeutics for the pharmaceutical industry primarily due to the issues surrounding their inclusion in drug payment plans and diversion of resources for their research. These drugs have been a point of contention also because of a lack of clarity in defining them. For the purpose of this report, lifestyle diseases have been defined to include a range of indications that affect an individual's quality of life even though they may not be deemed a medical problem.
The market was led by the MDD therapeutic segment followed by hormonal contraceptives. The smallest indication among the lifestyle disorders was alcohol dependence. The overall market was $37.2bn but is forecast to decline, albeit with a low single digit CAGR over the 2008-14 period.
Lifestyle disorders are marked by slowed R&D process and limited investigational products though MDD reflects some differences to this scenario. Each of the therapeutic indication s considered in this report reflects a markedly different scenario that substantiates the investment case around them. For instance:
- In the antidepressants market , the older antidepressants such as tricyclic s and monoamine oxidase inhibitors, have given way to agents that target metabolism, storage and release neurotransmitters such as serotonin and norepinephrine. - In case of obesity, compounds with novel mechanisms of action such as GLP-1 pathway, monoamine transmission, PTP-1B receptor and melanin system, are being investigated. - The hormonal contraceptives market is marked with little R&D that has led to gaps in contraceptive technology. The industry needs to invest in contraceptives with better side-effects profile to aid compliance. - Growth of the erectile dysfunction market would be determined by the market dynamics ensuing between Viagra, Cialis and Levitra. - In the smoking cessation market, growth prospects of the leading brands such as Pfizer's Chantix, are likely to be determined by the market's response to the black box label warnings on neuropsychiatric effects, introduced in July 2009.
Key features of this report - Epidemiological analysis of the therapeutic segments and forecast prevalence over the period 2008-14 - Forecasts and analysis of the key products in the lifestyle disorders market over the period 2008-14, across major classes of treatments - Overview of key events in the global lifestyle disorders market that have impacted treatment trends and sales potential. - Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios - Detailed analysis of the major classes of treatments across all the therapeutic segments analyzed in the report - Detailed analysis of the clinically differentiated products in the lifestyle disorders market pipeline and sales forecast of key R&D pipeline products in the global lifestyle disorders market
Scope of this report - Develop insights into patient potential with the report's coverage of the therapy area and leading lifestyle disorders players today. - Quickly understand how recent events are affecting the performance of major products and how leading players are confronting competitive challenges in the lifestyle disorders marketplace. - Gain up-to-date market intelligence across the lifestyle disorders category and understand the major issues affecting key pharmaceutical marketers. - Understand which drug classes have the greatest potential to drive lifestyle disorders franchise growth, and how pharmaceutical companies are attempting to capitalize these market opportunities. - Compare the franchises of leading pharmaceutical marketers across key therapeutic classes and understand how market share of leading companies will evolve over the next six years.
Key Market Issues - Reimbursement of lifestyle drugs replete with challenges The reimbursement of lifestyle drugs is a much debated subject in most nations. This is primarily because most lifestyle disorders tend to be non-life threatening. One of the key drugs that brought into light the issues around reimbursement of lifestyle drugs has been Viagra, launched in 1998. Viagra's launch raised concerns among governments and insurers about the budgetary implications of its reimbursement. - The global contraceptives market - slowed R&D Use of contraceptives has increased across different categories of women population and across geographies as well. However there is still need for further market penetration of contraceptives. The key concerns that women tend to have are the actual and perceived side effects of their use. From the industry front, there is little R&D in this therapeutic category that has led to gaps in contraceptive technology. - CNS side-effects limiting the growth of smoking cessation products Sanofi-Aventis terminated the development of its smoking cessation product Dianicline citing reasons that it was not differentiated adequately from Chantix. As the drug has the same mechanism of action as Chantix, the likely CNS side-effects made it less attractive. In July 2009, the FDA had added black box label warning on neuropsychiatric effects on Chantix and Zyban labels, which is likely to impede their growth over the forecast period.
Key findings from this report - The R&D pipeline for lifestyle disorders shows a lot of variation across indications. For conditions such as MDD, there are several compounds under different investigational stages (both early and late) while indications such as alopecia reflect slowed R&D process. - The antidepressants market R&D has been evolving and newer therapies have been emerging. The older antidepressants gave way to agents that target metabolism, storage and release of neurotransmitters such as serotonin and norepinephrine. The newer antidepressants such as SSRIs and SNRIs have a much better safety and side effects profile and have taken precedence in the less severe depression market. - The global contraceptives market presents opportunities for companies to invest in considering the little R&D in this therapeutic category that has led to gaps in contraceptive technology. There is much scope for the industry to invest in contraceptives with better side-effects profile to aid compliance. - Three closely-watched obesity drugs are currently under development - Arena Pharmaceuticals' lorcaserin, Vivus' Qnexa and Orexigen Therapeutics 'Contrave . With few drug options in the obesity market, any approval would mark the first new obesity drug to enter the market in ten years.
Key questions answered - Which companies were the leading players in the lifestyle disorders therapy area in 2008? - How have recent major launches from the key market players performed? - Which companies will become the key players in the lifestyle disorders market over the period 2008-14? - Which products will be impacted by generic competitors over the period 2008-14? - Which pipeline products are expected to generate sustainable revenue growth?
Table of Contents The Lifestyle Disorders Market Outlook to 2014 Executive Summary 10 Lifestyle diseases - an overview 10 Global market analysis 11 Key investigational compounds 12 Competitive landscape 13 Scope and methodology 14 Scope 14 Methodology 14
Chapter 1 Lifestyle diseases - an overview 18 Summary 18 Introduction 19 Defining lifestyle diseases 20 Alcohol dependence 22 Chronic effects 22 Alopecia 23 Classification of Alopecia 23 Major depressive disorder (MDD) 24 Obesity 26 Causes of obesity 26 Hormonal contraception 28 Erectile dysfunction 29 Smoking cessation 30 Quitting 31 Treatment 31 Characteristics of lifestyle drugs 32 Simple dosing regimen 32 Fast onset of action 33 Tolerable side effects 33 Epidemiology of lifestyle diseases 33 Reimbursement of lifestyle drugs 38 Reimbursement of Viagra in the US 38 Reimbursement of Viagra in the EU 39 Reimbursement of other lifestyle drugs - issues and challenges 41
Chapter 2 Global market analysis 44 Summary 44 Introduction 45 Key recent events 45 Swiss Competition Commission imposes penalty on leading players 45 Naltrexone not shown to be effective for substance abuse in schizophrenics 45 Xenical and Alli being assessed for risk of liver injury 46 The global contraceptives market still presents investment opportunities 46 Market analysis for leading lifestyle indications 47 Major depressive disorder (MDD) 48 Introduction 48 Analysis of drug classes 49 Leading treatment brands 51 Trends in generics usage 54 Hormonal contraception 54 Introduction 54 Analysis of drug classes 55 Leading treatment brands 56 Trends in generics usage 58 Erectile dysfunction 58 Introduction 58 Analysis of drug classes 59 Leading treatment brands 60 Trends in generics usage 61 Smoking cessation 62 Introduction 62 Analysis of drug classes 62 Leading treatment brands 64 Trends in generics usage 65 Obesity 66 Introduction 66 Analysis of drug classes 67 Leading treatment brands 68 Trends in generics usage 70 Alcohol dependence 70 Introduction 70 Analysis of drug classes 71 Leading treatment brands 72 Trends in generics usage 73 Alopecia 73 Introduction 73 Analysis of drug classes 74 Leading treatments 75 Lifestyle disorders sales forecast 76 Leading brands dynamics 77 Leading brands sales forecasts 79
Chapter 3 Key investigational compounds 82 Summary 82 Introduction 83 Key trends in R&D 83 Obesity - different mechanisms of action being explored 83 Campral the first new drug in alcohol dependence in two decades 83 Vivitrol potential being explored in opioid dependence 84 Antabuse - a novel mechanism of action but presents compliance issues 84 Evolving novel mechanisms of action in the MDD market 84 Sanofi-Aventis terminated development of smoking cessation product Dianicline 85 Profiles of leading drugs in development 85 Compounds awaiting regulatory approval compounds 86 WC 3016 (Norethindrone/ethinyl estradiol) - Warner Chilcott 86 Qnexa (phentermine/topiramate) - Vivus 88 APD356 (lorcaserin) - Arena 89 Phase III compounds 91 Contrave (bupropion/naltrexone) - Orexigen 91 The increasingly competitive obesity environment 92 Vilazodone - Clinical Data 94 F2695 (levomilnacipran) - Pierre Fabre/Forest 95 TA-1790 (avanafil) - Mitsubishi Tanabe/Vivus 96 NicVAX - Nabi Biopharmaceuticals/GSK 97 NIC002 (CYT002-NicQb) - Novartis/Cytos 99 Naltrexone depot - Elbion AG 100 Key investigational compounds sales forecast 101
Chapter 4 Competitive landscape 104 Summary 104 Introduction 105 Wyeth 108 Overview 108 Drug class focus 108 Marketed products portfolio 109 R&D pipeline analysis 110 Strategic growth analysis 110 Drivers of growth 110 Resistors to growth 111 Eli Lilly 111 Overview 111 Drug class focus 112 Marketed products portfolio 113 R&D pipeline analysis 114 Strategic growth analysis 114 Drivers of growth 114 Resistors to growth 115 Pfizer 115 Overview 115 Drug class focus 115 Marketed products portfolio 116 R&D pipeline analysis 118 Strategic growth analysis 118 Drivers of growth 118 Resistors to growth 118 Bayer 119 Overview 119 Drug class focus 119 Marketed products portfolio 120 R&D pipeline analysis 121 Strategic growth analysis 121 Drivers of growth 121 Resistors to growth 122 Forest 122 Overview 122 Drug class focus 122 Marketed products portfolio 123 R&D pipeline analysis 124 Strategic growth analysis 125 Drivers of growth 125 Resistors to growth 125 Dynamics of the leading alopecia market players 126 The competitive positioning of leading generic players 127
Chapter 5 Appendix 128 IMS data 128 Glossary 129 Index 131
Browse the complete Report on: http://www.reportsandreports.com/market-reports/the-lifestyle-disorders-market-outlook-to-2014-reimbursement-iss/
Related Reports: http://www.reportsandreports.com/market-reports/blood-and-lymphatic-system-hemophilia-or-blood-coagulation-disord/ http://www.reportsandreports.com/market-reports/the-future-of-blood-disorders-therapeutics-analysis-and-market-f/ http://www.reportsandreports.com/market-reports/advances-in-ophthalmology-markets-in-the-treatment-of-eye-disorde/
About Us ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.